Welcome to our dedicated page for SpyGlass Pharma SEC filings (Ticker: SGP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SpyGlass Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SpyGlass Pharma's regulatory disclosures and financial reporting.
Khan Bilal Arshad reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 13,700 shares. Following the reported transactions, holdings were 13,700 shares.
SpyGlass Pharma director Habib J. Dable was granted stock options to acquire 27,400 shares of common stock on February 5, 2026. The options have an exercise price of $16 per share and were awarded as a derivative security grant.
According to the award terms, the options vest over three years, with one thirty-sixth of the shares vesting each month after the grant date, so long as Dable continues to serve as an Outside Director under the company’s 2026 Equity Incentive Plan.
Pardo Geoffrey B reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
Dybbs Michael reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
SpyGlass Pharma director Elizabeth G. O'Farrell received a stock option grant covering 13,700 shares of common stock on February 5, 2026. The option has an exercise price of $16 per share, expires on February 5, 2036, and was awarded at no cost to her.
The option will vest 100% on the earlier of one year after the grant date or immediately before the next annual meeting of stockholders, provided she continues as an Outside Director. Following this grant, she beneficially owns options for 13,700 shares directly.
Dennewill James Robert Jr. reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 105,000 shares. Following the reported transactions, holdings were 105,000 shares.
Pujara Chetan Pratap reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 105,000 shares. Following the reported transactions, holdings were 105,000 shares.
SpyGlass Pharma, Inc. director and officer Malik Y. Kahook received a grant of stock options covering 105,000 shares of common stock on February 5, 2026 at an exercise price of $16 per share. These options are held as direct beneficial ownership.
The options vest over time: 25% of the shares vest on the one-year anniversary of the February 5, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments over the following three years. The options expire on February 5, 2036, and this grant brings his total derivative holdings from this award to 105,000 options.
SpyGlass Pharma, Inc. granted its Chief Financial Officer, Jean-Frederic Viret, a stock option covering 17,500 shares of common stock at an exercise price of $16 per share on February 5, 2026.
According to the vesting terms, 25% of the option vests on the one-year anniversary of the February 5, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service. After this grant, Viret directly holds derivative securities representing 17,500 underlying shares.
SpyGlass Pharma, Inc. Chief Executive Officer and director Patrick H. Mooney reported the acquisition of a stock option grant for 300,000 shares of common stock. The option has an exercise price of $16 per share and is held as a direct ownership position.
The grant vests over four years starting from a vesting commencement date of February 5, 2026. Twenty-five percent of the shares vest on the one-year anniversary of that date, and the remaining shares vest in equal monthly installments thereafter, contingent on Mr. Mooney continuing as a service provider.